NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

NCT04136184 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Interventions

DRUG: Inotersen
DRUG: Eplontersen

Sponsor

Ionis Pharmaceuticals, Inc.